Health Canada Authorizes Import of US Vasopressin Injection Amid Critical Shortage
According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.
Health Canada is permitting the temporary importation of US-authorized Vasopressin Injection to address a shortage of the Canadian-authorized version, noting significant differences in administration.
What this Health Canada recall tells you, and what most readers miss
This notice was issued by Health Canada on March 4, 2026 and geographically references Canada. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Product & Food Recalls — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly Health Canada detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized Health Canada recall is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (recall, product-safety, health-canada, pharmaceuticals) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What Happened
Health Canada has announced the exceptional, temporary importation and sale of US-authorized Vasopressin Injection, USP (20 units/mL) to address a current shortage of the Canadian-authorized version (DIN 02139502). The US-authorized product, manufactured by Fresenius Kabi USA, LLC, is similar but not identical to the Canadian product. Specifically, the US version is intended for intravenous (IV) infusion, whereas the Canadian version is authorized for intramuscular (IM) or subcutaneous (SC) administration.
Which Products Are Affected
The following product is being imported from the United States to Canada:
- Product Name: Vasopressin Injection, USP
- Strength: 20 units/mL
- Format: 1 mL single-dose vial (Preservative-free)
- Manufacturer: Fresenius Kabi USA, LLC
- Importer: Fresenius Kabi Canada Ltd.
- Identifying Codes:
- Vial NDC: 63323-930-00
- Unit of Sale NDC: 63323-930-01 (Tray of 25 vials)
- Product Code: 930101
- Labeling: The imported product features English-only labels.
What You Should Do
Healthcare professionals, including emergency and critical care physicians, anesthesiologists, and pharmacists, are advised to:
- Verify Administration Route: Be aware that the US-authorized product is intended exclusively for IV infusion after dilution. It is not labeled for IM or SC use, and the safety of those administration routes has not been established for this specific formulation.
- Check for Differences: Note that the US product differs from the Canadian version in indication, packaging, formulation, dilution requirements, storage conditions, and in-use periods.
- Consult Documentation: Healthcare providers should consult the US Prescribing Information (USPI) for complete safety and administration details.
Why This Matters
The shortage of Canadian-authorized vasopressin presents serious risks to patients requiring therapy in critical care settings. While the imported US product provides a necessary alternative, the significant differences in administration routes and preparation requirements necessitate heightened awareness to prevent medical errors.
Source
Original source: Health Canada Official Notice ↗
Related Product & Food Recalls
All Product & Food Recalls →Frequently Asked Questions
Common questions about this Health Canada recall.
What is this Health Canada recall about? ▾
Which agency issued this alert? ▾
How severe is this alert? ▾
What area is affected? ▾
Where can I find more Product & Food Recalls updates? ▾
Primary source data
EPA Outdoor Air Quality Data
Federal monitoring network — every measurement we report
AirNow (EPA / NOAA)
Real-time AQI for every monitored U.S. location
National Weather Service
Active watches, warnings, and advisories — NOAA
CDC Air Quality & Health
Health-impact reference behind every AQI category